IONS,ABCL Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.98
Percentage change -3.15	%

Peers: BIIB REGN VRTX GILD NBIX ALNY PRTA ARWR SRPT FOLD

| Held by: VTI VB VXF VBK XBI IBB ARKG IWP SCHA IWF

Index	-	P/E	-	EPS (ttm)	-3.04	Insider Own	2.75%	Shs Outstand	157.91M	Perf Week	-9.81%
Market Cap	4.80B	Forward P/E	-	EPS next Y	-3.02	Insider Trans	-3.87%	Shs Float	154.59M	Perf Month	-9.10%
Income	-453.55M	PEG	-	EPS next Q	-1.08	Inst Own	100.60%	Short Float	8.29%	Perf Quarter	-16.96%
Sales	705.56M	P/S	6.80	EPS this Y	-26.33%	Inst Trans	1.17%	Short Ratio	7.96	Perf Half Y	-26.59%
Book/sh	3.73	P/B	8.10	EPS next Y	21.26%	ROA	-15.13%	Short Interest	12.81M	Perf Year	-32.45%
Cash/sh	14.49	P/C	2.08	EPS next 5Y	21.36%	ROE	-93.03%	52W Range	30.23 - 52.34	Perf YTD	-13.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-17.87%	52W High	-42.36%	Beta	0.27
Dividend TTM	-	Quick Ratio	8.43	Sales past 5Y	-5.56%	Gross Margin	95.27%	52W Low	-0.20%	ATR (14)	1.31
Dividend Ex-Date	-	Current Ratio	8.47	EPS Y/Y TTM	-18.79%	Oper. Margin	-67.22%	RSI (14)	37.05	Volatility	3.58% 3.98%
Employees	1069	Debt/Eq	3.33	Sales Y/Y TTM	-10.48%	Profit Margin	-64.28%	Recom	1.81	Target Price	57.14
Option/Short	Yes / Yes	LT Debt/Eq	3.31	EPS Q/Q	-953.12%	Payout	-	Rel Volume	1.27	Prev Close	31.15
Sales Surprise	67.73%	EPS Surprise	41.29%	Sales Q/Q	-30.15%	Earnings	Feb 19 BMO	Avg Volume	1.61M	Price	30.17
SMA20	-8.00%	SMA50	-7.21%	SMA200	-23.20%	Trades		Volume	2,040,088	Change	-3.15%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Redburn Atlantic	Neutral	$39
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$67 → $60
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$53 → $62
Jul-16-24	Resumed	Jefferies	Buy	$29 → $75
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform	$44
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $40
Sep-09-22	Resumed	Morgan Stanley	Overweight	$57
Jul-18-22	Resumed	Oppenheimer	Outperform	$59
Mar-31-22	Resumed	Piper Sandler	Overweight	$54
Mar-01-22	Initiated	Guggenheim	Buy	$64
Mar-01-22	Initiated	Citigroup	Sell	$26
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform	$40 → $30

Show Previous Ratings

Today 07:05AM	Ionis to present at upcoming investor conferences (Business Wire)
Mar-28-25 11:30AM	Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? (Zacks)
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-27-25 11:32AM	Ionis and Sobi agree on olezarsen commercialisation (Pharmaceutical Technology)
08:31AM	IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi (Zacks)
07:00AM	Loading…
Mar-26-25 07:00AM	Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. (Business Wire)
Mar-25-25 05:42PM	Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-24-25 08:00AM	Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-21-25 11:30AM	Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report? (Zacks)
Mar-12-25 01:46PM	Ono earmarks $940m to gain rare blood cancer therapy from Ionis (Pharmaceutical Technology)
09:56AM	Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal (Benzinga)
07:12AM	Ono pays $280M to license Ionis rare disease drug (BioPharma Dive)
Mar-11-25 06:00PM	Ionis and Ono announce global license agreement for sapablursen in polycythemia vera (Business Wire)
Mar-10-25 07:00AM	WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy (Business Wire)
Feb-27-25 02:09AM	Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ... (GuruFocus.com)
07:05AM	Loading…
Feb-25-25 07:05AM	Ionis to present at upcoming investor conferences (Business Wire)
Feb-21-25 09:35AM	Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James (TipRanks)
Feb-20-25 12:14PM	Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
10:31AM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
07:00AM	New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control (Business Wire)
04:16AM	Q4 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:10AM	Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
Feb-19-25 12:11PM	Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales (Benzinga)
09:30AM	Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:19AM	Ionis Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports fourth quarter and full year 2024 financial results (Business Wire)
Feb-18-25 04:08PM	Ionis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In January (Insider Monkey)
Feb-17-25 09:16AM	Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-12-25 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
01:59PM	Loading…
Feb-11-25 01:59PM	Why Insiders Are Selling Ionis Pharmaceuticals, Inc. (IONS) Recently (Insider Monkey)
Feb-08-25 09:28AM	Why Ionis Pharmaceuticals, Inc. (IONS) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-05-25 07:05AM	Ionis to hold fourth quarter and full year 2024 financial results webcast (Business Wire)
Jan-23-25 07:30AM	FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA (GlobeNewswire) +6.03%
Jan-17-25 11:22AM	Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-15-25 09:17AM	Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034 (GlobeNewswire)
Jan-13-25 08:00AM	Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum (PR Newswire)
Jan-12-25 09:00PM	Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities (GlobeNewswire)
Jan-08-25 04:11PM	Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-20-24 07:44PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
03:09PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:23AM	FDA approves Ionis TRYNGOLZA for FCS treatment (Pharmaceutical Technology)
07:24AM	FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood (Benzinga)
06:00AM	Ionis gets a milestone approval; Another top FDA official to step down (BioPharma Dive)
Dec-19-24 06:28PM	TRYNGOLZA (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet (PR Newswire)
Dec-11-24 09:55AM	How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% (Zacks)
Dec-08-24 05:55PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Dec-06-24 11:31AM	Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-05-24 07:35AM	Theratechnologies enters exclusive licensing agreement with Ionis (TipRanks)
Nov-27-24 12:00PM	Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Nov-26-24 08:00AM	Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-21-24 05:22PM	Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-19-24 07:08PM	Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
Nov-18-24 09:35AM	Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks (Zacks)
Nov-07-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
05:15AM	Ionis announces design for Phase III trial of Angelman syndrome therapy (Clinical Trials Arena)
04:26AM	Q3 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:18AM	Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com)
Nov-06-24 09:45AM	Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? (Motley Fool)
09:30AM	Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:07AM	Ionis Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome (PR Newswire)
07:00AM	Ionis reports third quarter 2024 financial results (PR Newswire)
Nov-04-24 09:44AM	Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE (PR Newswire)
09:16AM	Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Oct-30-24 10:01AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-23-24 07:05AM	Ionis to hold third quarter 2024 financial results webcast (PR Newswire)
Oct-22-24 07:41AM	EU CHMP recommends AstraZeneca and Ionis Wainzua for ATTRv-PN (Pharmaceutical Technology)
Oct-21-24 02:08AM	WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (PR Newswire)
Oct-09-24 04:11PM	Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds (Insider Monkey)
Oct-08-24 07:30AM	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA (GlobeNewswire)
Oct-03-24 07:00AM	New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (PR Newswire)
Oct-01-24 06:59PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
07:00AM	Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease (PR Newswire)
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
Sep-09-24 09:10PM	Ionis announces pricing of $500.3 million public offering (PR Newswire) -12.29%
04:20PM	Ionis announces proposed public offering of common stock (PR Newswire)
Sep-04-24 08:00AM	Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations (GlobeNewswire)
07:30AM	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA (GlobeNewswire)
Aug-28-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Aug-15-24 09:15AM	Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth? (Zacks)
Aug-13-24 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 11:34PM	Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary (GuruFocus.com)
Aug-02-24 01:32PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:54AM	Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises (Zacks)
04:34AM	Q2 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 10:00AM	Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:20AM	Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Ionis Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports second quarter 2024 financial results (PR Newswire)
Jul-31-24 09:00AM	Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx System for Administration of nusinersen (PR Newswire)
Jul-25-24 10:02AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-23-24 09:53AM	Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study (Zacks)
07:03AM	Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug (Clinical Trials Arena)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily) +5.83%
08:14AM	Ionis plots next steps for Angelman drug Biogen passed on (BioPharma Dive)
07:00AM	Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome (PR Newswire)
Jul-19-24 09:56AM	Ionis (IONS) Completes Enrolment for Rare Disease Drug Study (Zacks)
08:24AM	Ionis to hold second quarter 2024 financial results webcast (PR Newswire)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Monia Brett P	Chief Executive Officer	Mar 11 '25	Sale	32.32	140	4,525	180,980	Mar 13 04:45 PM
Monia Brett P	Officer	Mar 11 '25	Proposed Sale	32.32	140	4,525		Mar 11 04:04 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 20 '25	Sale	32.35	1,207	39,046	56,245	Feb 24 04:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 04 '25	Sale	31.62	6,165	194,939	57,452	Feb 06 06:27 PM
Monia Brett P	Chief Executive Officer	Feb 04 '25	Sale	31.65	38,843	1,229,463	180,683	Feb 06 06:26 PM
Monia Brett P	Officer	Feb 04 '25	Proposed Sale	32.13	40,003	1,285,296		Feb 04 04:56 PM
O'NEIL PATRICK R.	Officer	Feb 04 '25	Proposed Sale	32.13	7,372	236,862		Feb 04 04:45 PM
Swayze Eric	EVP Research	Jan 31 '25	Sale	32.31	1,367	44,162	48,017	Feb 03 07:27 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 31 '25	Sale	32.20	1,484	47,780	61,056	Feb 03 07:27 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 31 '25	Sale	32.49	1,406	45,685	63,617	Feb 03 07:27 PM
Monia Brett P	Chief Executive Officer	Jan 31 '25	Sale	32.45	13,242	429,655	219,526	Feb 03 07:26 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 31 '25	Sale	32.44	1,523	49,404	110,500	Feb 03 07:26 PM
Geary Richard S	EVP, Chief Development Officer	Jan 31 '25	Sale	32.40	1,406	45,561	99,077	Feb 03 07:26 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 31 '25	Sale	32.46	1,327	43,079	93,146	Feb 03 07:26 PM
Schneider Eugene	Officer	Jan 31 '25	Proposed Sale	33.00	1,700	56,100		Jan 31 05:43 PM
Geary Richard S	Officer	Jan 31 '25	Proposed Sale	35.00	1,910	66,850		Jan 31 05:41 PM
Swayze Eric	Officer	Jan 31 '25	Proposed Sale	35.00	1,857	64,995		Jan 31 05:03 PM
O'NEIL PATRICK R.	Officer	Jan 31 '25	Proposed Sale	35.00	1,910	66,850		Jan 31 05:02 PM
HOUGEN ELIZABETH L	Officer	Jan 31 '25	Proposed Sale	35.00	2,069	72,415		Jan 31 05:01 PM
BENNETT C FRANK	Officer	Jan 31 '25	Proposed Sale	35.00	1,803	63,105		Jan 31 04:59 PM
Monia Brett P	Officer	Jan 31 '25	Proposed Sale	33.53	13,242	444,010		Jan 31 04:58 PM
YANG MICHAEL J.	Director	Jan 15 '25	Option Exercise	0.00	1,931	0	1,931	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 15 '25	Option Exercise	0.00	49	0	206	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 15 '25	Option Exercise	0.00	19,111	0	52,824	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 16 '25	Sale	32.84	7,154	234,959	45,670	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 16 '25	Sale	32.70	22	719	184	Jan 17 07:41 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 15 '25	Option Exercise	0.00	17,372	0	65,031	Jan 17 07:41 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 16 '25	Sale	32.79	6,523	213,889	58,508	Jan 17 07:41 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 15 '25	Option Exercise	0.00	19,690	0	68,563	Jan 17 07:41 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 16 '25	Sale	32.83	7,360	241,629	61,203	Jan 17 07:41 PM
Monia Brett P	Chief Executive Officer	Jan 15 '25	Option Exercise	0.00	73,448	0	240,841	Jan 17 07:41 PM
Monia Brett P	Chief Executive Officer	Jan 16 '25	Sale	32.63	33,445	1,091,444	207,396	Jan 17 07:41 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 15 '25	Option Exercise	0.00	23,887	0	116,755	Jan 17 07:40 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 16 '25	Sale	32.81	8,870	290,989	107,885	Jan 17 07:40 PM
Geary Richard S	EVP, Chief Development Officer	Jan 15 '25	Option Exercise	0.00	18,901	0	103,735	Jan 17 07:40 PM
Geary Richard S	EVP, Chief Development Officer	Jan 16 '25	Sale	32.86	7,072	232,407	96,663	Jan 17 07:40 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 15 '25	Option Exercise	0.00	12,295	0	20,204	Jan 17 07:40 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 16 '25	Sale	32.78	4,267	139,855	15,937	Jan 17 07:40 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 15 '25	Option Exercise	0.00	14,283	0	60,451	Jan 17 07:40 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 16 '25	Sale	32.70	5,400	176,580	55,051	Jan 17 07:40 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 15 '25	Option Exercise	0.00	18,011	0	97,618	Jan 17 07:40 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 16 '25	Sale	32.90	6,752	222,114	90,866	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 15 '25	Option Exercise	0.00	2,460	0	4,100	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 15 '25	Option Exercise	0.00	8,787	0	28,418	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '25	Sale	32.70	3,401	111,213	25,017	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '25	Sale	32.70	1,029	33,648	3,071	Jan 17 07:40 PM
Swayze Eric	Officer	Jan 16 '25	Proposed Sale	32.70	7,154	233,936		Jan 16 07:31 PM
Schneider Eugene	Officer	Jan 16 '25	Proposed Sale	32.70	6,523	213,302		Jan 16 07:30 PM
O'NEIL PATRICK R.	Officer	Jan 16 '25	Proposed Sale	32.70	7,360	240,672		Jan 16 07:29 PM
Monia Brett P	Officer	Jan 16 '25	Proposed Sale	32.70	33,445	1,093,652		Jan 16 07:28 PM
HOUGEN ELIZABETH L	Officer	Jan 16 '25	Proposed Sale	32.70	8,870	290,049		Jan 16 07:25 PM
Geary Richard S	Officer	Jan 16 '25	Proposed Sale	32.70	7,072	231,254		Jan 16 07:23 PM
Devers Shannon L.	Officer	Jan 16 '25	Proposed Sale	32.70	4,267	139,531		Jan 16 07:22 PM
Birchler Brian	Officer	Jan 16 '25	Proposed Sale	32.70	5,400	176,580		Jan 16 07:21 PM
BENNETT C FRANK	Officer	Jan 16 '25	Proposed Sale	32.70	6,752	220,790		Jan 16 07:19 PM
Baroldi Joseph	Officer	Jan 16 '25	Proposed Sale	32.70	3,401	111,213		Jan 16 07:18 PM
Hayden Michael R	Director	Dec 23 '24	Buy	36.22	5,000	181,079	35,219	Dec 26 04:57 PM
Swayze Eric	EVP Research	Nov 12 '24	Sale	37.92	1,194	45,278	33,713	Nov 14 05:30 PM
Monia Brett P	Chief Executive Officer	Nov 12 '24	Sale	38.05	6,630	252,294	167,393	Nov 14 05:30 PM
LOSCALZO JOSEPH	Director	Nov 12 '24	Sale	37.86	13,508	511,426	32,251	Nov 14 05:30 PM
Monia Brett P	Officer	Nov 12 '24	Proposed Sale	38.89	6,629	257,774		Nov 12 04:17 PM
Swayze Eric	Officer	Nov 12 '24	Proposed Sale	38.88	1,194	46,422		Nov 12 04:16 PM
LOSCALZO JOSEPH	Officer	Nov 12 '24	Proposed Sale	38.88	13,508	525,152		Nov 12 04:15 PM
Swayze Eric	EVP Research	Oct 15 '24	Option Exercise	0.00	125	0	210	Oct 17 06:42 PM
Swayze Eric	EVP Research	Oct 16 '24	Sale	38.31	53	2,031	157	Oct 17 06:42 PM
Geary Richard S	EVP, Chief Development Officer	Aug 29 '24	Sale	49.63	331	16,428	84,823	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 28 '24	Sale	49.16	320	15,731	85,154	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 05 '24	Sale	48.00	2,430	116,640	85,508	Aug 06 05:27 PM
Geary Richard S	Executive Vice President, Chie	Aug 05 '24	Proposed Sale	49.13	3,128	153,678		Aug 05 04:11 PM
WENDER JOSEPH H	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	132,756	Jul 17 05:03 PM
PARSHALL B LYNNE	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	87,265	Jul 17 05:03 PM
LOSCALZO JOSEPH	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	45,759	Jul 17 05:03 PM
KLEIN JOSEPH III	Director	Jul 16 '24	Option Exercise	24.42	12,000	293,040	12,000	Jul 17 05:02 PM
KLEIN JOSEPH III	Director	Jul 16 '24	Sale	50.00	12,000	600,000	0	Jul 17 05:02 PM
HERMAN JOAN E	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	42,007	Jul 17 05:02 PM
Diaz Allene M.	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	17,353	Jul 17 05:02 PM
Diaz Allene M.	Director	Jul 16 '24	Sale	49.49	1,637	81,019	15,716	Jul 17 05:02 PM
BERTHELSEN SPENCER R	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	151,934	Jul 17 05:02 PM
BERTHELSEN SPENCER R	Director	Jun 17 '24	Option Exercise	35.53	16,000	568,480	163,257	Jun 20 05:52 PM
BERTHELSEN SPENCER R	Director	Jun 17 '24	Sale	40.29	16,000	644,640	147,257	Jun 20 05:52 PM
WENDER JOSEPH H	Director	May 09 '24	Option Exercise	35.53	16,000	568,480	128,079	May 13 05:25 PM
KLEIN JOSEPH III	Director	May 03 '24	Sale	42.71	6,000	256,277	0	May 07 04:55 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 15 '24	Option Exercise	0.00	10,838	0	23,637	Apr 17 05:19 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 16 '24	Sale	41.60	4,006	166,641	19,631	Apr 17 05:19 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 15 '24	Option Exercise	0.00	1,875	0	47,061	Apr 17 05:16 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 16 '24	Sale	41.66	905	37,698	46,156	Apr 17 05:16 PM

Dollar change -0.08
Percentage change -3.46	%

ABCL AbCellera Biologics Inc daily Stock Chart

Peers: REGN AMGN VRTX MRNA BNTX INCY ALNY NVAX IONS EXEL

| Held by: IBB SPDW IDNA ONEQ GWX LRNZ AVUS BBC AVSC BIB

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	24.97%	Shs Outstand	295.76M	Perf Week	-13.90%
Market Cap	664.51M	Forward P/E	-	EPS next Y	-0.65	Insider Trans	0.00%	Shs Float	223.58M	Perf Month	-13.73%
Income	-162.86M	PEG	-	EPS next Q	-0.14	Inst Own	37.05%	Short Float	10.19%	Perf Quarter	-26.40%
Sales	28.83M	P/S	23.05	EPS this Y	-10.53%	Inst Trans	11.77%	Short Ratio	5.61	Perf Half Y	-12.89%
Book/sh	3.57	P/B	0.62	EPS next Y	-6.97%	ROA	-11.43%	Short Interest	22.79M	Perf Year	-50.33%
Cash/sh	2.19	P/C	1.02	EPS next 5Y	-9.14%	ROE	-14.75%	52W Range	2.11 - 4.75	Perf YTD	-23.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-107.74%	ROI	-14.58%	52W High	-53.05%	Beta	0.48
Dividend TTM	-	Quick Ratio	9.81	Sales past 5Y	376.38%	Gross Margin	-236.40%	52W Low	5.69%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	9.81	EPS Y/Y TTM	-9.24%	Oper. Margin	-1091.65%	RSI (14)	36.73	Volatility	4.97% 6.17%
Employees	596	Debt/Eq	0.06	Sales Y/Y TTM	-24.17%	Profit Margin	-564.81%	Recom	1.25	Target Price	10.50
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	28.84%	Payout	-	Rel Volume	0.84	Prev Close	2.31
Sales Surprise	-32.70%	EPS Surprise	9.98%	Sales Q/Q	-44.98%	Earnings	Feb 27 AMC	Avg Volume	4.06M	Price	2.23
SMA20	-6.46%	SMA50	-21.32%	SMA200	-20.88%	Trades		Volume	3,411,129	Change	-3.46%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy	$9
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$6
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight	$20
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy	$30
Nov-16-22	Initiated	Truist	Buy	$29
Dec-21-21	Initiated	The Benchmark Company	Buy	$27
Nov-19-21	Initiated	Piper Sandler	Overweight	$33
Jan-05-21	Initiated	SVB Leerink	Outperform	$45
Jan-05-21	Initiated	Stifel	Buy	$59
Jan-05-21	Initiated	Credit Suisse	Outperform	$52
Jan-05-21	Initiated	BMO Capital Markets	Outperform	$48
Jan-05-21	Initiated	Berenberg	Buy	$53

Show Previous Ratings

Mar-25-25 04:30PM	AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 (Business Wire)
Feb-28-25 02:18PM	Q4 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -11.47%
02:43AM	AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ... (GuruFocus.com)
Feb-27-25 10:15PM	AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript (Motley Fool)
06:15PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	AbCellera Reports Full Year 2024 Business Results (Business Wire)
Feb-26-25 07:55AM	What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earnings (GuruFocus.com)
Feb-11-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in March (Business Wire) +5.08%
Jan-21-25 04:05PM	AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 (Business Wire) +15.36%
Jan-17-25 07:53AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jan-15-25 10:47AM	AbbVie and Simcere Zaiming link to develop trispecific antibody (Pharmaceutical Technology) +6.86%
Jan-14-25 09:25AM	AbCellera expands collaboration with AbbVie (TipRanks) -7.67%
Jan-13-25 09:00AM	AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology (Business Wire)
Jan-07-25 09:11AM	Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? (Insider Monkey)
Nov-21-24 04:05PM	AbCellera to Present at Upcoming Investor Conferences in December and January (Business Wire)
10:05AM	Loading…
Nov-07-24 10:05AM	AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 (Business Wire)
Nov-05-24 11:17AM	Q3 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -5.88%
02:11AM	AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Nov-04-24 11:00PM	AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript (Motley Fool) +5.86%
05:55PM	AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q3 2024 Business Results (Business Wire)
Nov-01-24 09:06AM	AbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-22-24 04:05PM	AbCellera to Present at Upcoming Investor Conferences in November 2024 (Business Wire)
Oct-16-24 08:58AM	Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts? (Insider Monkey)
Oct-04-24 09:00AM	AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 (Business Wire)
Sep-26-24 04:05PM	AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 (Business Wire)
Sep-01-24 10:26PM	AbCellera Biologics Inc. (ABCL): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
04:05PM	AbCellera to Present at Upcoming Investor Conferences in September (Business Wire)
05:13AM	AbCellera Biologics Inc. (ABCL): A Top Contender Among Canadas Best Penny Stocks in 2024 (Insider Monkey)
12:45AM	Loading…
Aug-07-24 12:45AM	AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript (Motley Fool) -7.72%
Aug-06-24 06:15PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2024 Business Results (Business Wire)
Aug-01-24 06:32AM	AbCellera and Lilly broadens antibody discovery partnership (Pharmaceutical Technology) -6.44%
Jul-31-24 09:00AM	AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines (Business Wire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-09-24 12:00PM	AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-25-24 04:05PM	AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jun-13-24 05:40AM	Down 57%, Is AbCellera Biologics a Buy on the Dip? (Motley Fool)
May-28-24 04:05PM	AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 (Business Wire) +5.97%
May-13-24 06:00AM	3 Stock Gems Hiding in the Nasdaq (InvestorPlace)
May-08-24 11:03AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:01AM	Q1 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
04:30AM	AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript (Motley Fool)
May-07-24 08:57PM	ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:01PM	AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates (GuruFocus.com)
04:05PM	AbCellera Reports Q1 2024 Business Results (Business Wire)
May-01-24 09:00AM	AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies (Business Wire)
Apr-30-24 10:01AM	Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-08-24 12:05PM	AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 (Business Wire)
Apr-03-24 04:05PM	AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Mar-27-24 04:30PM	The 7 Best Penny Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-26-24 05:25PM	Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks (Insider Monkey) -6.33%
Mar-19-24 04:05PM	AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 (Business Wire)
Mar-11-24 09:00AM	AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions (Business Wire)
Mar-05-24 04:30PM	AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 (Business Wire)
Feb-26-24 06:55AM	3 Highly Rated Biotech Stocks to Buy for 300% Gains (InvestorPlace)
Feb-23-24 04:30PM	AbCellera Announces Resignation of Board Member (Business Wire)
Feb-22-24 08:15PM	AbCellera to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-21-24 09:22AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.42%
07:09AM	Q4 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 11:00PM	AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript (Motley Fool)
07:00PM	AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:57PM	AbCellera Biologics Inc (ABCL) Faces Net Loss in FY 2023 Amid Strategic Shifts (GuruFocus.com)
04:05PM	AbCellera Reports Full Year 2023 Business Results (Business Wire)
Jan-30-24 01:02PM	Baillie Gifford Adjusts Stake in AbCellera Biologics Inc (GuruFocus.com) -5.55%
Jan-23-24 04:05PM	AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 (Business Wire)
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-03-24 09:40AM	Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-20-23 04:05PM	AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 (Business Wire)
Dec-16-23 01:00PM	AI Meets Biotech: 3 Top Stocks Transforming Medical Science (InvestorPlace)
Dec-11-23 03:30PM	16 Best Penny Stocks To Buy For 2024 (Insider Monkey)
Nov-16-23 04:05PM	AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 (Business Wire)
Nov-03-23 12:05PM	AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 (Business Wire) +6.09%
10:51AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:42AM	Q3 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
05:55AM	Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress (GuruFocus.com)
05:30AM	AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-02-23 05:56PM	AbCellera Biologics Inc (ABCL) Reports Q3 2023 Earnings: Revenue Drops to $7 Million (GuruFocus.com) +7.52%
04:05PM	AbCellera Reports Q3 2023 Business Results (Business Wire)
Nov-01-23 04:05PM	Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology (GlobeNewswire)
Oct-31-23 04:05PM	AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023 (Business Wire)
Oct-26-23 10:02AM	Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline (Zacks)
Oct-11-23 04:05PM	AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire) -9.34%
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-27-23 09:00AM	AbCellera Announces Two T-Cell Engager Presentations at SITC 2023 (Business Wire)
Sep-20-23 05:02PM	AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron (Business Wire)
Sep-14-23 07:03PM	Insider Buying: Veronique Lecault Acquires 20,000 Shares of AbCellera Biologics Inc (GuruFocus.com)
Sep-13-23 09:00AM	AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology (Business Wire)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey) -6.03%
07:37AM	10 Stocks That Could 10X Over the Next 10 Years (Insider Monkey)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-04-23 10:23AM	Q2 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -13.34%
01:00AM	AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript (Motley Fool)
Aug-03-23 05:35PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2023 Business Results (Business Wire)
Jul-26-23 01:17PM	10 Best Canadian Stocks Under $10 (Insider Monkey)
Jul-25-23 09:55AM	Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect? (Zacks)
Jul-24-23 04:05PM	AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights Request for Rehearing (Business Wire)

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

IONS

Ionis Pharmaceuticals Inc

ABCL

AbCellera Biologics Inc

Upgrade your FINVIZ experience